TL/DR –
Donald Trump announced that all 50 states will participate in the Medicaid GENEROUS drug-pricing model, which aims to lower Medicaid prescription medicine costs through an international reference-pricing system. The model works by using manufacturer-reported pricing data from eight countries to calculate a target Medicaid net price, and then negotiate supplemental rebates to reduce the cost. The potential savings are uncertain and will depend heavily on which manufacturers participate, what drugs are included, the size of existing Medicaid rebates, and confidential international pricing information.
Trump Announces All-inclusive Medicaid Drug Price Deal Amid Midterm Elections
President Donald Trump has publicized all 50 states’ participation in his administration’s Medicaid GENEROUS drug-pricing model. This model seeks to reduce Medicaid’s prescription medicine expenses through an international reference-pricing system.
This announcement provides the Republicans a new healthcare policy success to flaunt amidst Democrats pushing healthcare affordability, Medicare, and prescription drug costs as focal points in the upcoming midterm elections.
This new initiative could lower pharmaceutical spending for state and federal Medicaid programs with new manufacturer rebates. However, experts believe that the actual savings will depend on the participating drugs and manufacturers.
How Does Trump’s GENEROUS Medicaid Model Function?
The GENEROUS model, an acronym for “GENErating cost Reductions fOr U.S. Medicaid,” operates through the existing Medicaid Drug Rebate Program. It enables the Centers for Medicare & Medicaid Services (CMS) to negotiate supplemental rebate agreements with participating pharma manufacturers.
Under this model, CMS determines an MFN price for participating drugs using manufacturing-reported pricing data from eight countries. CMS then negotiates supplemental rebates intended to bring Medicaid’s net price down to this level.
The program focuses on brand-name drugs, including single-source and innovator multiple-source medicines. States can choose which eligible drugs they want covered under the model but must adopt standardized coverage criteria negotiated by CMS and manufacturers.
Why Do Analysts Believe Savings Remain Uncertain?
While the White House claims that broader MFN drug-pricing initiatives could save taxpayers billions of dollars over the next decade, health policy researchers say many critical variables remain unknown. These include participating manufacturers, included drugs, size of existing Medicaid rebates, and confidential international pricing information.
KFF notes that Medicaid already receives some of the most significant prescription-drug discounts in the U.S. healthcare system. Its analysis found that rebates reduced gross Medicaid prescription-drug spending by an average of 53 percent between fiscal years 2019 and 2024.
Are Healthcare and Medicare Still Key Midterm Issues?
According to a January KFF Health Tracking Poll, healthcare continues to influence voters’ decisions in November’s elections. Most notably, 66 percent of Americans worry about affording healthcare for themselves or their families, and 55 percent said their healthcare costs had increased over the previous year.
Simultaneously, prescription drug prices seem to be one of the few healthcare issues where Republicans have closed the gap. KFF found voters nearly evenly divided on which party they trusted more to address prescription drug prices.
Can Trump’s Drug Pricing Initiative Help Republicans?
Despite the challenging electoral environment for Republicans, Trump’s securing participation from every state in the GENEROUS model could provide the GOP with a tangible healthcare initiative to reference in the campaign’s final weeks. Whether voters regard this as a significant step toward lowering prescription drug costs may help ascertain the political value the White House ultimately reaps from this announcement.
—
Read More Health & Wellness News ; US News